Item 2.02. Results of Operations and Financial Condition.
On March 6, 2019, Seres Therapeutics, Inc. (the Company) announced its financial results for the year and quarter ended
December 31, 2018 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) shall
not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
The following exhibit relates to Item 2.02, which shall be deemed to be furnished, and not filed: